Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
Phase 1
Completed
- Conditions
- Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
- Interventions
- Registration Number
- NCT04500860
- Lead Sponsor
- Kasr El Aini Hospital
- Brief Summary
Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome
- Detailed Description
90 female patients with overactive bladder syndrome divided into 3 groups group A subjected to daily low dose tadalafil 5 mg ,group B subjected to tolterodine and group C to placebo. They are evaluated as using OAB symptoms score for 6 months follow up
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
- any female with overactive bladder syndrome, urgency with or without urgency urinary incontinence
Exclusion Criteria
- Active Urinary tract infection
- neurologic abnormality
- Pure Stress urinary incontinence
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group B Tolterodine Tolterodine 4 Mg Oral Capsule, Extended Release 30 patients subjected to tolterodine 4 mg daily Group C placebo Placebo 30 patients subjected to placebo daily Group A Tadalafil 5 mg Low dose tadalafil 5 mg 30 patients subjected to Daily dose of tadalafil 5mg
- Primary Outcome Measures
Name Time Method Efficacy of daily low dose tadalafil 5mg in treatment of female overactive bladder syndrome: 6 months follow up 6 months Evaluation of efficacy of tadalafil 5 mg
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Samer Morsy
🇪🇬Cairo, Egypt